Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;109(11):3745-3750.
doi: 10.3324/haematol.2023.284786.

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry

Charles Herbaux  1 , Caroline Bret  2 , Emmanuel Bachy  3 , Pierre Bories  4 , Roberta Di Blasi  5 , Alexis Cuffel  5 , Thomas Gastinne  6 , Thierry Lamy  7 , Mikael Roussel  7 , Krimo Bouabdallah  8 , David Beauvais  9 , Guillaume Cartron  2 , Jacques-Olivier Bay  10 , Didier Blaise  11 , Marie-Therese Rubio  12 , Mohamad Mohty  13 , Fabien Le Bras  14 , Olivier Casasnovas  15 , Julien Guy  15 , Stephanie Guidez  16 , Cristina Castilla Llorente  17 , Olivier Hermine  18 , Laurianne Drieu La Rochelle  19 , Sylvain Carras  20 , Blandine Guffroy  21 , Sophie Caillat-Zucman  5 , Roch Houot  7 , Steven Le Gouill  22
Affiliations

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry

Charles Herbaux et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Characteristics of the intention-to-treat population. (A) Description of the different sets of patients. (B) Overall survival (OS) since inclusion in the DESCAR-T intention-to-treat (ITT) cohort. (C) OS since inclusion in the DESCAR-T cohort according to treatment set. CI: confidence interval; NA: not available.
Figure 2.
Figure 2.
Efficacy description of all patients who received brexucel. (A and B) Outcome of patients in the treated set, progression-free survival (PFS) and overall survival (OS), respectively. (C) OS according to response after bridging strategy, responders are defined as patients achieving partial or complete response. (D) OS according to C-reactive protein (CRP) level the day of brexu-cel infusion. (E) OS according to ferritin level the day of brexu-cel infusion. CI: confidence interval; NA: not available.
See this image and copyright information in PMC

References

    1. Martin P, Maddocks K, Leonard JP, et al. . Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559-1563. - PubMed
    1. Jain P, Kanagal-Shamanna R, Zhang S, et al. . Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578-587. - PubMed
    1. Jain P, Kanagal-Shamanna R, Zhang S, et al. . Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol. 2021;96(5):E137-E140. - PubMed
    1. Wang M, Munoz J, Goy A, et al. . KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. - PMC - PubMed
    1. Wang Y, Jain P, Locke FL, et al. . Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594-2606. - PMC - PubMed